Medicinova (MNOV) Long-Term Investments (2011 - 2022)

Medicinova's (MNOV) quarterly Long-Term Investments came in at $10.0 million in Q3 2022, up 1525.19% on a QoQ basis from $616657.0 in Q1 2018.

Medicinova (MNOV) Long-Term Investments (2011 - 2022) Analysis & Trends

Medicinova (MNOV) has 9 years of Long-Term Investments data on file, last reported at $10.0 million in Q3 2022.

On a quarterly basis, Long-Term Investments changed N/A year-over-year to $10.0 million in Q3 2022; TTM through Sep 2022 was $10.0 million, a N/A change from a year earlier, with the FY2017 full-year figure at $616657.0, changed 0.27% from the prior year.
Long-Term Investments for Q3 2022 stood at $10.0 million, up from $616657.0 in the prior quarter.
Over the last five years, Long-Term Investments for MNOV reached as high as $10.0 million in Q3 2022 and fell as low as $616657.0 in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	505,194.89
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Medicinova	64.48 Mn	64.48 Mn	4,754.00	-

Download Data